Octreotide improves human lymphatic fluid transport a translational trial
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Octreotide improves human lymphatic fluid transport a translational trial. / Holm-Weber, Thomas; Skov, Frederik; Mohanakumar, Sheyanth; Thorup, Lene; Riis, Troels; Christensen, Mikkel Bring; Sonne, David Peick; Jensen, Per Bo; Bødtkjer, Donna Briggs; Hjortdal, Vibeke Elisabeth.
In: European Journal of Cardio-Thoracic Surgery, Vol. 65, No. 1, 380, 2024.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Octreotide improves human lymphatic fluid transport a translational trial
AU - Holm-Weber, Thomas
AU - Skov, Frederik
AU - Mohanakumar, Sheyanth
AU - Thorup, Lene
AU - Riis, Troels
AU - Christensen, Mikkel Bring
AU - Sonne, David Peick
AU - Jensen, Per Bo
AU - Bødtkjer, Donna Briggs
AU - Hjortdal, Vibeke Elisabeth
N1 - Publisher Copyright: # The Author(s) 2023.
PY - 2024
Y1 - 2024
N2 - OBJECTIVES: Chylothorax is a complex condition and many different pharmacological agents have been tried as treatment. Octreotide is used off-label to treat chylothorax, but the efficacy of octreotide remains unclear. A decrease in lymph production is suggested as the mechanism. In this cross-over study, we explore the direct effect of octreotide on human lymphatic drainage. METHODS: Pre-clinical: the effect of octreotide on force generation was assessed during acute and prolonged drug incubation on human lymphatic vessels mounted in a myograph. Clinical: in a double-blinded, randomized, cross-over trial including 16 healthy adults, we administered either octreotide or saline as an intravenous infusion for 2.5 h. Near-infrared fluorescence imaging was used to examine spontaneous lymphatic contractions and lymph pressure in peripheral lymphatic vessels and plethysmography was performed to assess the capillary filtration rate, capillary filtration coefficient and isovolumetric pressures of the lower leg. RESULTS: Pre-clinical: human thoracic duct (n ¼ 12) contraction rate was concentration-dependently stimulated by octreotide with a maximum effect at 10 and 100 nmol/l in the myograph chamber. Clinical: spontaneous lymphatic contractions and lymph pressure evaluated by near-infrared fluorescence did not differ between octreotide or placebo (P ¼ 0.36). Plethysmography revealed similar capillary filtration coefficients (P ¼ 0.057), but almost a doubling of the isovolumetric pressures (P ¼ 0.005) during octreotide infusion. CONCLUSIONS: Octreotide stimulated lymphatic contractility in the pre-clinical setup but did not affect the spontaneous lymphatic contractions or lymph pressure in healthy individuals. Plethysmography revealed a doubling in the isovolumetric pressure. These results suggest that octreotide increases lymphatic drainage capacity in situations with high lymphatic afterload.
AB - OBJECTIVES: Chylothorax is a complex condition and many different pharmacological agents have been tried as treatment. Octreotide is used off-label to treat chylothorax, but the efficacy of octreotide remains unclear. A decrease in lymph production is suggested as the mechanism. In this cross-over study, we explore the direct effect of octreotide on human lymphatic drainage. METHODS: Pre-clinical: the effect of octreotide on force generation was assessed during acute and prolonged drug incubation on human lymphatic vessels mounted in a myograph. Clinical: in a double-blinded, randomized, cross-over trial including 16 healthy adults, we administered either octreotide or saline as an intravenous infusion for 2.5 h. Near-infrared fluorescence imaging was used to examine spontaneous lymphatic contractions and lymph pressure in peripheral lymphatic vessels and plethysmography was performed to assess the capillary filtration rate, capillary filtration coefficient and isovolumetric pressures of the lower leg. RESULTS: Pre-clinical: human thoracic duct (n ¼ 12) contraction rate was concentration-dependently stimulated by octreotide with a maximum effect at 10 and 100 nmol/l in the myograph chamber. Clinical: spontaneous lymphatic contractions and lymph pressure evaluated by near-infrared fluorescence did not differ between octreotide or placebo (P ¼ 0.36). Plethysmography revealed similar capillary filtration coefficients (P ¼ 0.057), but almost a doubling of the isovolumetric pressures (P ¼ 0.005) during octreotide infusion. CONCLUSIONS: Octreotide stimulated lymphatic contractility in the pre-clinical setup but did not affect the spontaneous lymphatic contractions or lymph pressure in healthy individuals. Plethysmography revealed a doubling in the isovolumetric pressure. These results suggest that octreotide increases lymphatic drainage capacity in situations with high lymphatic afterload.
KW - Chylothorax
KW - Clinical study
KW - Lymphatic
KW - Near-infrared fluorescence imaging
KW - Octreotide
KW - Randomized cross-over study
U2 - 10.1093/ejcts/ezad380
DO - 10.1093/ejcts/ezad380
M3 - Journal article
C2 - 37951584
AN - SCOPUS:85183994184
VL - 65
JO - European Journal of Cardio-thoracic Surgery
JF - European Journal of Cardio-thoracic Surgery
SN - 1010-7940
IS - 1
M1 - 380
ER -
ID: 383745246